Author:
Orkin Chloe,DeJesus Edwin,Sax Paul E,Arribas Jose R,Gupta Samir K,Martorell Claudia,Stephens Jeffrey L,Stellbrink Hans-Jurgen,Wohl David,Maggiolo Franco,Thompson Melanie A,Podzamczer Daniel,Hagins Debbie,Flamm Jason A,Brinson Cynthia,Clarke Amanda,Huang Hailin,Acosta Rima,Brainard Diana M,Collins Sean E,Martin Hal
Subject
Virology,Infectious Diseases,Immunology,Epidemiology
Reference22 articles.
1. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel;Saag;JAMA,2018
2. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidance,2018
3. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial;Wohl;Lancet HIV,2019
4. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
5. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial;Gallant;Lancet,2017
Cited by
87 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献